Aligos, Amoytop Partner for Hepatitis B Trial

Xiamen Amoytop Biotech Co., Ltd. and ligos Therapeutics, a biopharmaceutical business, have signed a clinical trial partnership agreement. Under the terms of the agreement, a Phase 1b exploratory clinical trial will be sponsored and carried out in China to assess the safety and effectiveness of ALG-000184 in combination with PEGBING® (Mipeginterferon alfa-2b) in patients with chronic hepatitis B (CHB). Following permission by China's National Medical Products Administration, the clinical investigation is anticipated to start.

For CHB, a strong oral small molecule capsid assembly modulator (CAM-E) called ALG-000184 is being developed. It is intended to take advantage of the dual function of CAMs by decreasing the expression of viral indicators like DNA, RNA, and pertinent antigens, hence upsetting the levels of hepatitis B cccDNA and its generated transcripts. In longer-term Phase 1b studies, ALG-000184 monotherapy has shown best-in-class reductions in HBV DNA, RNA, HBsAg, HBeAg, and HBcrAg without viral breakthrough to date.

PEGBING®, independently developed by Amoytop, is the world's first 40kD pegylated interferon α-2b injection; it is primarily used in the clinical treatment of viral hepatitis and is the first-line medication for the antiviral treatment of chronic hepatitis B, which is crucial in raising the clinical cure rate of hepatitis B and lowering the risk of liver cancer. The Phase 1b study will be a randomised, double-blinded, active-controlled study to assess the safety, pharmacokinetics